SANTA MONICA, Calif. – GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.
As Novo Nordisk brings the Ozempic pill to market, we’re focused on helping patients access it with clear, transparent pricing,” said Wendy Barnes, President & CEO of GoodRx. “The availability of an oral formulation under the Ozempic brand marks an important step forward, offering a convenient alternative to the established injectable. It also reflects GoodRx’s expanding work with Novo Nordisk across the entire semaglutide portfolio and its role in supporting patient access.”
“We’re excited to bring the Ozempic pill to the GoodRx platform – adding a newly approved oral option under a brand people know and trust, and giving healthcare professionals more flexibility to tailor treatment for each patient,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Working with GoodRx helps expand access to our medicines, now including the Ozempic pill, with a clear self-pay pricing model.”
More broadly, this announcement demonstrates how GoodRx is evolving beyond a pricing solution into a broader consumer access platform for pharmaceutical manufacturers, helping them reach patients directly, convert clinically appropriate demand, and deliver transparent pricing seamlessly at the pharmacy counter.
The Ozempic pill is now available to eligible self-pay patients at a cash price of $149 per month for the 1.5mg dose, $199 per month for the 4mg dose, and $299 per month for the 9mg dose.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
